Diana Swift

1 week ago | portugues.medscape.com | Diana Swift

Muitas mães que fazem o aleitamento materno apresentam sinais e sintomas semelhantes aos da menopausa. Esse quadro, observado no puerpério, foi recentemente descrito como “síndrome geniturinária da lactação” em um artigo de revisão sistemática publicado no periódico Obstetrics & Gynecology. O termo foi proposto em 2024 após discussões interdisciplinares entre ginecologistas, obstetras e urologistas, e após o reconhecimento da síndrome geniturinária da menopausa.

2 weeks ago | medscape.com | Diana Swift

Many breastfeeding mothers experience menopause-like symptoms of the postpartum condition recently designated genitourinary syndrome of lactation (GSL) in a systematic review reported in Obstetrics & Gynecology. The term was proposed in 2024 after interdisciplinary discussions among obstetricians, gynecologists, and urologists and following recognition of the genitourinary syndrome of menopause (GSM).

2 weeks ago | oncologynewscentral.com | Diana Swift

The American Society of Clinical Oncology (ASCO) has updated its guidelines on indications for sentinel lymph node biopsy (SLNB) in breast cancer. The new recommendations have the potential to “significantly alter current practice,” according to one of the update’s authors. Recent data suggest that SLNB can be omitted in select patients after initial surgery for early breast cancer (stages I and II).

2 weeks ago | medscape.com | Diana Swift

A self-collection (SC) device that could easily be used at home proved safe and accurate for cervical screening in the SELF-CERV prospective nonrandomized clinical trial, as reported in JAMA Network Open. Known as the Teal Wand, the device was recently approved by the US Food and Drug Administration (FDA) for home use.

2 weeks ago | portugues.medscape.com | Diana Swift

Pacientes adultos com esteato-hepatite associada à disfunção metabólica e fibrose hepática moderada ou avançada apresentaram melhora histológica com uma dose semanal de semaglutida (Wegovy), segundo informações de um ensaio clínico randomizado e controlado por placebo em andamento. O agonista do receptor do peptídeo 1 glucagonoide (GLP-1) é atualmente candidato ao tratamento da esteato-hepatite associada à disfunção metabólica.